SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegat ...

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. for allegedly misleading investors regarding the operational status of the Brook Mine in Wyoming, which was described as a "hoax" by Wolfpack Research [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Ramaco securities between July 31, 2025, and October 23, 2025 [1][2]. - Investors have until March 31, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations - A report by Wolfpack Research claimed that the Brook Mine had no meaningful activity since its groundbreaking, contradicting the company's previous statements [3]. - Following the report, Ramaco's stock price dropped by $3.81, nearly 10%, closing at $36.01 per share [3]. Group 3: Company Background - Ramaco Resources, Inc. is headquartered in Lexington, Kentucky, and focuses on coal mining and mineral projects across the United States [2].

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) for securities fraud, alleging that the company made materially false statements and failed to disclose significant safety concerns regarding its drug DCCR during the class period from March 26, 2025, to November 4, 2026 [1] Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased SLNO common stock during the specified class period and have until May 5, 2026, to file a lead plaintiff motion [1] - The complaint alleges that Soleno's Phase 3 clinical trial for DCCR downplayed and concealed safety concerns, leading to materially greater risks than disclosed [1] - The lawsuit claims that positive statements made by Soleno regarding its business and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Stock Price Impact - Following the publication of a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell by $9.27 per share, or 11.98%, closing at $68.09 on August 18, 2025 [1] - After a patient death linked to DCCR was disclosed on September 10, 2025, the stock price dropped by $13.49 per share, or 19.21%, closing at $56.72 on September 11, 2025 [1] - On November 4, 2025, Soleno reported that the Scorpion Capital report had disrupted DCCR's launch, resulting in a further decline of $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [1] Group 3: Company Background - Soleno Therapeutics is focused on developing treatments for rare diseases, specifically targeting Prader-Willi syndrome with its drug DCCR [1] - The company has faced significant scrutiny regarding the safety and efficacy of its drug, which has impacted investor confidence and stock performance [1]

Core Viewpoint - BellRing Brands, Inc. is facing a federal securities class action lawsuit due to allegations of making false or misleading statements regarding its sales growth and competition impact, with a lead plaintiff deadline set for March 23, 2026 [1] Summary by Relevant Sections Company Overview - BellRing Brands, Inc. (NYSE: BRBR) is under investigation by Faruqi & Faruqi, LLP for potential securities fraud claims [1] Allegations - The complaint alleges that BellRing and its executives violated federal securities laws by failing to disclose the strength and sustainability of sales growth and the competitive landscape affecting product demand [1] Stock Performance - On May 5, 2025, BellRing announced that several key retailers reduced their weeks of supply, leading to a stock price decline of $14.88 per share, or 19%, from $78.43 to $63.55 on May 6, 2025 [1] - On August 4, 2025, disappointing quarterly consumption of Premier Protein RTD Shakes resulted in a further stock price drop of $17.46 per share, or nearly 33%, from $53.64 to $36.18 on August 5, 2025 [1] Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [1] - Members of the putative class can choose to serve as lead plaintiff or remain absent, with their ability to recover unaffected by this decision [1]

Core Viewpoint - The Law Offices of Frank R. Cruz is encouraging shareholders of PayPal Holdings, Inc. (PYPL) to inquire about a potential securities fraud class action lawsuit [1] Group 1 - The law firm is actively seeking to represent shareholders who may have been affected by alleged securities fraud involving PayPal [1] - The announcement indicates a growing concern among investors regarding the company's practices and transparency [1] - This legal action could have implications for PayPal's stock performance and investor confidence [1]

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Alexandria Real Estate Equities, Inc. (ARE) Shareholders To Inquire About Securities Fraud Class Action. ...

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [2]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [2]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [2]. Group 2: Lead Plaintiff Process - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [3]. - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3]. Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].

Core Viewpoint - The Law Offices of Frank R. Cruz is encouraging shareholders of Avantor, Inc. (AVTR) to inquire about a potential securities fraud class action lawsuit [1] Group 1 - The law firm is actively seeking shareholders who may have been affected by the alleged securities fraud [1] - The announcement indicates a growing concern regarding the company's practices and potential legal implications [1] - Shareholders are urged to gather information and consider their options in light of the situation [1]

Core Viewpoint - The Law Offices of Frank R. Cruz is encouraging shareholders of Synopsys, Inc. (SNPS) to inquire about a potential securities fraud class action lawsuit [1] Group 1 - The law firm is actively seeking shareholders who may have been affected by the alleged securities fraud [1] - The announcement indicates a focus on protecting shareholder rights and addressing potential financial losses [1] - The firm is likely to investigate the circumstances surrounding the alleged fraud to determine the validity of claims [1]

Core Points - A class action lawsuit has been filed against V.F. Corporation (VFC) by Berger Montague on behalf of investors who purchased shares between October 30, 2023, and May 20, 2025 [1][2] - The lawsuit claims that VFC misled investors regarding the effectiveness of its turnaround plan, particularly for the Vans brand, failing to disclose necessary restructuring steps that were already in progress [3][4] - Following a report of a 20% decline in Vans revenue for Q4 fiscal 2025, VFC's stock price dropped over 15% in a single day, indicating significant investor concern [4] Company Overview - V.F. Corporation, headquartered in Denver, Colorado, is a global leader in branded lifestyle apparel, footwear, and accessories, owning well-known brands such as Vans, The North Face, Timberland, and JanSport [2] Financial Performance - In Q4 fiscal 2025, Vans revenue declined by 20%, worsening from an 8% decline in the previous quarter, attributed to undisclosed internal cost-cutting and restructuring actions [4] - VFC indicated that even without these restructuring measures, Vans would have experienced a high single-digit revenue decline, raising concerns about deeper issues within the brand [4]